Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.66 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31441725 | 1.00 | AAK1 (0.66) | AAK1IRAK4KCNH2ATRATRIP | |
| SCHEMBL17099735 | 0.91 | AAK1 (0.72) | AAK1NTRK1SMOGAANPSR1 | |
| SCHEMBL29398697 | 0.91 | AAK1 (0.72) | AAK1NTRK1SMOGAANPSR1 | |
| SCHEMBL31441491 | 0.88 | AAK1 (0.59) | AAK1TYK2 | |
| SCHEMBL31441602 | 0.88 | AAK1 (0.63) | AAK1IRAK4ATRATRIPNTRK1 | |
| SCHEMBL31441547 | 0.88 | AAK1 (0.63) | AAK1IRAK4ATRATRIPNTRK1 | |
| SCHEMBL31441562 | 0.88 | AAK1 (0.63) | AAK1IRAK4ATRATRIPNTRK1 | |
| SCHEMBL31441605 | 0.88 | AAK1 (0.63) | AAK1IRAK4ATRATRIPNTRK1 | |
| SCHEMBL31441539 | 0.88 | AAK1 (0.63) | AAK1IRAK4ATRATRIPNTRK1 | |
| SCHEMBL31441524 | 0.88 | AAK1 (0.58) | AAK1NTRK1TYK2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-08-28 | — | — | US | disclosed |
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-04-17 | — | — | US | disclosed |
| WO-2025054448-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, CAMKK1, AP2A1 | AAK1 1/4885IRAK4 325/4885KCNH2 4251/4885 |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, AP2A1, CSNK1A1 | AAK1 1/4885IRAK4 542/4885KCNH2 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.